US/UK/Canada

Share

Quotes

The goal is to attract a licensing partner after completing phase I/II in order to continue the development. An alternative scenario is to find a partner before entering clinical studies, based on a precise development plan
Suzanne Kilany, CRD Aptahem
It is a very exciting result for any drug candidate to trigger a protein like Pentraxin-3 with such a broad spectrum of effects
Luiza Jedlina, CSO Aptahem
Aptahem is currently focusing on sepsis, but there is possibility for potentially expanding the indication. At present, no such decision has been made, but we are not ruling it out
Mikael Lindstam, CEO Aptahem
Pick a time period -
Tags ( Active)

Aptahem enters strategic collaboration agreement with e-Projection to more efficiently achieve partnership in Japan

Aptahem AB (publ), a biotech company developing treatments for patients suffering from acute inflammatory diseases such as sepsis, announces today that the company enters into a strategic collaboration agreement with the Japanese company e-Projection to accelerate potential partnering opportunities with pharma and biotech companies in Japan. E-Projection acts in the area of business development with focus on the Japanese market and has the advantage of knowledge in language, culture, networks and experience which has been essential for Aptahem to enter into an agreement. The agreement

Aptahem's Scientific Collaboration on Apta-1’s Mechanism of Action Accepted for Publication in the British Journal of Pharmacology

Aptahem announced today that their scientific collaboration with Örebro University has led to a groundbreaking manuscript, which has been accepted for publication in the prestigious British Journal of Pharmacology (BJP). BJP is one of the highest-ranked scientific journals globally, placing in the top 5th percentile with an impact factor of approximately 7. This recognition underscores the importance of Aptahem's development research and its potential contribution to pharmacological science.The article, titled “Antithrombotic but not anticoagulant activity of the thrombin-binding RNA

Aptahem comments on interesting data after finalised phase 1 study

Aptahem AB (publ), a biotechnology company developing treatments for patients suffering from acute inflammatory diseases such as sepsis, today announced that the completed double-blind randomised placebo-controlled phase 1 study in healthy volunteers also showed indications of drug efficacy.1. Aptahem has summarised and concluded all additional analyses taking into account the recently completed phase 1 study. 2. At dosing, interesting immunological marker responses were noted in the subjects, prompting further analyses and evaluation of safety and mechanism of action. 3. The analyses

Aptahem receives patent protection in Israel for patent family 2

Aptahem AB (publ) announces today that the company has received patent protection in Israel for patent family 2 from the Israeli Patent Office.With the approval in Israel of patent application 273759, the protection of the company’s drug candidate Apta-1 within patent family 2 in Israel, Israeli Patent No. 273759, is valid until the end of 2038. For further information: Aptahem ABMikael Lindstam, CEOTel: +46 (0)766-33 36 99E-mail: ml@aptahem.com About Aptahem Aptahem AB (APTA) is a clinical stage biotechnology company that develops RNA-based pharmaceuticals for the

Aptahem reports the FIH study on Apta-1 has been finalized

Aptahem AB (publ), a biotech company developing treatments for patients suffering from acute inflammatory diseases such as sepsis, today announces that the report on the First in Human (FIH) study has been finalized. The final study report confirms the previous top line results. The study is now closed and reported to the authorities.The top line results previously communicated from the study shows that Apta-1 has been well tolerated in the given doses. No serious side effects were seen and all participants fulfilled the study. In the additional analyzes that were performed during the study

Aptahem plans to perform a Proof-of-Concept Phase 2 study in patients with its lead candidate Apta-1

Aptahem AB (publ), a biotech company developing treatments for patients suffering from acute inflammatory diseases such as sepsis, today announces that the company has decided to revise its clinical development strategy by performing a Proof-of-Concept (PoC) study in patients as the next step in the clinical development of the drug candidate Apta-1. The aim with the planned study is to evaluate effect of Apta-1 in patients with acute and serious inflammatory diseases. The final study design is now under evaluation.After analyzing the results from the performed Phase 1a study, including the

Aptahem reports top line results from the FIH study with Apta-1

Aptahem AB (publ), a biotech company developing treatments for patients suffering from acute inflammatory diseases such as sepsis, today announces top line results from the First in Human (FIH) study. The aim of the study was to evaluate safety and tolerability with the company’s lead candidate Apta-1 which was performed as a dose escalating study in healthy volunteers.The unblinded data from the study shows that Apta-1 has been well tolerated in the given doses. No serious side effects were seen and all participants fulfilled the study. In the additional analyzes that were performed during

Aptahem’s CSO to present at Biologics World Nordics Conference

Aptahem’s CSO Dr Luiza Jedlina has been invited to speak at the Biologics World Nordics conference in Copenhagen on 7 March 2024.The title of the presentation is ”A Novel RNA Aptamer Targets Exosite 2 on Thrombin, Offering a Potential Treatment for Systemic Inflammation through a Unique Mechanism”. More about the conference is found via this link . For further information: Aptahem ABMikael Lindstam, CEOTel: +46 (0)766-33 36 99E-mail: ml@aptahem.com About Aptahem Aptahem AB (APTA) is a clinical stage biotechnology company

BioStock: Aptahem comments on the publication in Cells

Aptahem’s collaboration with the research group at the University Health Network in Toronto, has now resulted in a publication in the scientific journal Cells. BioStock reached out to Aptahem’s CEO Mikael Lindstam to find out more about what this means for the company.Read the full interview with Mikael Lindstam at biostock.se: https://www.biostock.se/en/2024/02/aptahem-comments-on-the-publication-in-cells/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/

Aptahem’s scientific manuscript now published in the journal Cells

Aptahem announced on the 27 February 2024 that the company’s scientific manuscript had been accepted for publication in the journal Cells. Today, the 28 February 2024, the paper has been published.The title of the manuscript is ”Therapeutic effects of a novel aptamer on coronaviral infection induced lung injury and systemic inflammatory responses” and can be accessed via this link . The manuscript describes the results of the preclinical studies performed in SARS Corona virus models in collaboration with the research group in Toronto, which indicate

Aptahem’s scientific manuscript in collaboration with the research group at UHN in Toronto has been approved for publication in the journal Cells

The ground-breaking results from the studies performed with the drug candidate Apta-1, in collaboration with the research group at University Health Network (UHN) in Toronto, in various serious disease models have now lead to a first approval for publication.The collaboration with the group in Toronto, lead by Professor Mingyao Liu, and from Aptahem Dr Luiza Jedlina, has been ongoing for some time and included several study steps in a SARS (Severe Acute Respiratory Syndrome) Corona lung model, which Aptahem previously has reported. The SARS Corona virus which has been used in the studies is

Aptahem receives Notice of Allowance in Israel for patent family 2

Aptahem AB (publ) announces today that the company has received a Notice of Allowance in Israel of the patent application no 273759 entitled A nucleic acid molecule with anti-inflammatory and anti-coagulant and organ-protective properties.The notice of allowance is a formal communication from the patent authority in which it indicates that the patent application has reached the status where it is allowed for issuance as a patent. When issued, the patent will be valid until, and including, 2038. CEO Mikael Lindstam comments: ”I am very pleased to receive the news that yet another

Aptahem finalizes Part 1a of the FIH study for its lead candidate Apta-1

Aptahem AB (publ), a biotech company developing treatments for patients suffering from acute inflammatory diseases such as sepsis, announces today the finalization of FIH (First In Human) Part 1a study.This decision is based on the data of the extra analyses leading to a more complete understanding of Apta-1´s mechanism of action. The decision will potentially save time moving forward with the clinical development program. The Phase 1a study is a so called dubble blind study and analysis and compilation of the unblinded results will now commence. Aptahem will present preliminary data when

BioStock Investor Meeting: Aptahem

Aptahem presented at BioStock Investor Meeting, September 20. The event took place in Stockholm, featuring several exciting life science companies presenting their business cases to investors and potential partners.See the presentation via: BioStock Investor Meeting September 2023 | Aptahem - YouTube  See the interview via (in Swedish):  BioStock Investor Meeting | Intervju med Aptahem | September 2023 - YouTube  This is a press release from BioStock - Connecting Innovation &

Aptahem reports promising outcome from the additional analyses on the mechanism on lead candidate Apta-1 in the FIH study

Aptahem AB (publ) announces today that the results from the additional analyses performed in cohorts 1 to 4 in the First in Human (FIH) study, have contributed to the clarification of Apta-1's impact on clinical biomarkers. Next step is to apply for approval to continue the study.Aptahem has now finalized the analyses recommended by the Data Review Committee. The data showed promising results regarding the effect of Apta-1 on clinical biomarkers. Aptahem will swiftly compile the data and aim to submit to the Ethics Committee and Competent Authority as soon as possible after the data review

Aptahem attends the BioStock Investor Meeting on 20 September 2023

Aptahem’s CEO Mikael Lindstam is presenting the company and gives an update on the ongoing activities. The presentation, which is held in English, can be followed at the physical event in Stockholm on 20 September at 15.00 CET.More information about the event and link to registration page is available on the BioStock website . For further information: Aptahem ABMikael Lindstam, CEOTel: +46 (0)766-33 36 99E-mail: ml@aptahem.com About Aptahem Aptahem AB (APTA) is a

BioStock article: Aptahem's CEO comments on Q2 and looks ahead

For Aptahem, the second quarter continued to focus on the clinical development of drug candidate Apta-1 against sepsis. However, the company recently put the clinical phase Ia study on hold after making, what it called, interesting findings. BioStock talked to CEO Mikael Lindstam to get an update.Read the interview with Aptahem's CEO Mikael Lindstam at Aptahem’s website . For further information: Aptahem ABMikael Lindstam, CEOTel: +46 (0)766-33 36 99E-mail: ml@aptahem.com About Aptahem

BioStock: Aptahem's CEO comments on Q2 and looks ahead

For Aptahem, the second quarter continued to focus on the clinical development of drug candidate Apta-1 against sepsis. However, the company recently put the clinical phase Ia study on hold after making, what it called, interesting findings. BioStock talked to CEO Mikael Lindstam to get an update.Read the full interview with Mikael Lindstam at biostock.se: https://www.biostock.se/en/2023/09/aptahems-ceo-comments-on-q2-and-looks-ahead/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/

BioStock-article: Aptahem comments on the paused phase I study

Aptahem develops the drug candidate Apta-1 as an acute treatment of sepsis. Recently, the company announced that the ongoing phase Ia study had been temporarily paused after observing interesting data. To learn more about the significance of this data, BioStock contacted Aptahem’s CEO Mikael Lindstam.Read the full interview with Mikael Lindstam at biostock.se: https://www.biostock.se/en/2023/07/aptahem-comments-on-the-paused-phase-i-study/ For further information: Aptahem ABMikael Lindstam, CEOTel: +46 (0)766-33 36 99E-mail: ml@aptahem.com About Aptahem Aptahem AB (APTA)

BioStock: Aptahem comments on the paused phase I study

Aptahem develops the drug candidate Apta-1 as an acute treatment of sepsis. Recently, the company announced that the ongoing phase Ia study had been temporarily paused after observing interesting data. To learn more about the significance of this data, BioStock contacted Aptahem’s CEO Mikael Lindstam.Read the full interview with Mikael Lindstam at biostock.se: https://www.biostock.se/en/2023/07/aptahem-comments-on-the-paused-phase-i-study/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/

In Aptahem’s FIH study further analytic studies will be performed

Aptahem AB (publ), a biotech company developing treatments for patients suffering from acute inflammatory diseases such as sepsis, announces today that in the double-blinded randomized placebo controlled first-in-human (FIH) clinical trial further analytic studies on the mechanism of Apta-1 are recommended which will result in a temporary hold of the study.During the course of the study, additional analyses have been performed, which indicated interesting findings. After reviewing the data, the Data Review Committee concluded that further assays would be recommended. Aptahem are using this

BioStock: Aptahem takes the next step in the treatment of sepsis

Sepsis affects millions of people globally every year and results in significant morbidity and mortality. The standard treatment consists mainly of antibiotics, which is not optimal given the risk of antibiotic resistance. A company whose goal is to develop the next generation of emergency drugs against the indication, is Swedish Aptahem with their drug candidate Apta-1.Read the article at biostock.se: https://www.biostock.se/en/2023/06/aptahem-takes-the-next-step-in-the-treatment-of-sepsis/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.

Aptahem’s poster presented at the ISTH conference now available

Aptahem participates in the conference International Society on Thrombosis and Haemostasis (ISTH) on 24-28 June where CSO Dr Luiza Jedlina has presented a poster.The poster, entitled “The RNA aptamer, Apta-1 targeting evolutionarily conserved motif on thrombin cures endotoxemia and reduces thrombosis in animal models by inhibiting aggregation and secretion of platelets”, is now available on Aptahem’s website: https://aptahem.com/research-and-development/publications/ For further information: Aptahem ABMikael Lindstam, CEOTel: +46 (0)766-33 36 99E-mail: ml@aptahem.com About

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe